Download Files:
Ubrogepant
$320 – $1,360
Products Details
Product Description
– Ubrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (CGRP) antagonist in development for acute treatment of migraine[1].
Web ID
– HY-12366
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C29H26F3N5O3
References
– [1]Li CC, et al. Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling. J Clin Pharmacol. 2017 Nov 14. doi: 10.1002/jcph.1021.
CAS Number
– 1374248-77-7
Molecular Weight
– 549.54
Compound Purity
– 99.69
SMILES
– O=C(C1=CN=C2C(C[C@@]3(C4=CC=CN=C4NC3=O)C2)=C1)N[C@@H]5C(N(CC(F)(F)F)[C@H](C)[C@H](C6=CC=CC=C6)C5)=O
Clinical Information
– Launched
Research Area
– Neurological Disease; Cardiovascular Disease
Solubility
– DMSO : 250 mg/mL (ultrasonic)
Target
– CGRP Receptor
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
